Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis.
In a general population survey in the United States, the prevalence of antiviral-agent-resistant herpes simplex virus was very low among more than 1,000 isolates from individuals with an episode of recurrent herpes labialis not treated with topical antiviral agents. Two isolates had borderline resistance to acyclovir (0.2%), and all were susceptible to penciclovir.
GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey KT15 0DE, United Kingdom. teresa.h.bacon@gsk.com
Teresa H
TH
Bacon
Ron J
RJ
Boon
Margaret
M
Schultz
Cheryl
C
Hodges-Savola
D000212:Acyclovir / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000287:Administration, Topical; D000328:Adult; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D024882:Drug Resistance, Viral; D005260:Female; D006147:Guanine; D006560:Herpes Labialis / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects; D006801:Humans; D008297:Male; D011153:Population; D011817:Rabbits; D012008:Recurrence; D014481:United States / Q000453:epidemiology
D000998:Antiviral Agents; C053539:penciclovir; D006147:Guanine; D000212:Acyclovir